论文部分内容阅读
早先的一项开放研究表明,对于存在多重冠心病危险因素(高VLDL甘油三脂,低HDL胆固醇和高空腹血糖)的高血压患者,多沙唑嗪对代谢有有益的作用。Andersson PE等据此进行了一项双盲、平行分组研究,对同时患有高甘油三脂血症和高血压患者使用多沙唑嗪和依那普利治疗6个月,以阐明多沙唑嗪对代谢的影响。胰岛素敏感性使用正常血糖高敏感性胰岛素钳夹技术测定。相对于依那普利,多沙唑嗪对胰岛素敏感性的提高更明显(21％,P=0．02),而且同时降低了血清甘油三脂(23％,P=0．01),VLDL甘油三脂(30％．P=0．08)以及VLDL胆固醇(24％,P=0．02)。多沙唑嗪的这种降脂作用是由于血浆脂蛋白
A previous open-label study showed that doxazosin has a beneficial effect on metabolism in hypertensive patients with multiple coronary heart disease risk factors (high VLDL triglycerides, low HDL cholesterol and high fasting glucose). Andersson PE et al accordingly conducted a double-blind, parallel-grouping study of doxazosin and enalapril in patients with both hypertriglyceridemia and hypertension at 6 months to elucidate the effects of doxazosin The impact of oxazine on metabolism. Insulin sensitivity was measured using normal glucose high sensitivity insulin clamp technique. Compared with enalapril, doxazosin increased insulin sensitivity more significantly (21%, P = 0.02), and at the same time decreased serum triglyceride (23%, P = 0.01), VLDL Triglyceride (30% .P = 0.08) and VLDL cholesterol (24%, P = 0.02). This lipid-lowering effect of doxazosin is due to plasma lipoprotein